Medical Transcription Billing Corp (NASDAQ:MTBC) Director John N. Daly sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 20th. The shares were sold at an average price of $4.70, for a total value of $47,000.00. Following the completion of the sale, the director now owns 115,000 shares of the company’s stock, valued at approximately $540,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of NASDAQ MTBC traded down $0.12 during trading hours on Friday, reaching $4.63. The stock had a trading volume of 167,692 shares, compared to its average volume of 251,401. The firm has a market capitalization of $57.10 million, a price-to-earnings ratio of -35.62 and a beta of 1.83. Medical Transcription Billing Corp has a 52-week low of $1.32 and a 52-week high of $5.44.

Medical Transcription Billing (NASDAQ:MTBC) last announced its quarterly earnings results on Wednesday, August 8th. The technology company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). The firm had revenue of $8.68 million during the quarter, compared to analyst estimates of $8.39 million. Medical Transcription Billing had a positive return on equity of 2.01% and a negative net margin of 2.73%. equities research analysts anticipate that Medical Transcription Billing Corp will post -0.5 earnings per share for the current year.

A number of analysts recently issued reports on the company. HC Wainwright set a $6.00 price target on Medical Transcription Billing and gave the company a “buy” rating in a report on Monday, August 13th. Chardan Capital reiterated a “buy” rating and issued a $2.75 price target on shares of Medical Transcription Billing in a report on Saturday, May 5th. Summer Street reiterated a “buy” rating on shares of Medical Transcription Billing in a report on Saturday, May 5th. Finally, ValuEngine upgraded Medical Transcription Billing from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Medical Transcription Billing currently has a consensus rating of “Buy” and a consensus target price of $3.92.

An institutional investor recently raised its position in Medical Transcription Billing stock. Macquarie Group Ltd. lifted its position in Medical Transcription Billing Corp (NASDAQ:MTBC) by 59.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 100,401 shares of the technology company’s stock after purchasing an additional 37,501 shares during the period. Macquarie Group Ltd. owned 0.85% of Medical Transcription Billing worth $389,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 5.66% of the company’s stock.

Medical Transcription Billing Company Profile

Medical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company’s offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform.

See Also: Do closed-end mutual funds pay dividends?

Receive News & Ratings for Medical Transcription Billing Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medical Transcription Billing and related companies with MarketBeat.com's FREE daily email newsletter.